Utrecht, The Netherlands and Cambridge, England - March 27, 2006: PanGenetics BV, a company devoted to the clinical development of therapeutic antibodies, today announced the closing of an oversubscribed €13 million series B round led by ABN AMRO Capital, with participation from Crédit Agricole Private Equity and Series A seed investor, Index Ventures. The company also announced the appointment of Dr Kevin Johnson, former board member and CTO at Cambridge Antibody Technology, as Chief Executive Officer.
